KRYS
$316.58-4.07%
as of close, Oct 16, 2026
☾ AH $316.58 -4.07%
Krystal Biotech Inc.Stock · HealthcareRussell 2000 0.3%Nasdaq Composite 0.02%US Stock Market 0.01%Russell 3000 0.01%
KRYS SEC filings (2026)
CIK 1711279 · Biological Products, (No Diagnostic Substances) (SIC 2836) · fiscal year ends in December
509 filings on EDGAR since 2017 · 9 annual, 27 quarterly, 112 current · financial statements · earnings
Latest 10-K
Feb 17, 2026
fiscal year to Dec 31, 2025
Latest 10-Q
Aug 3, 2026
quarter to Jun 30, 2026
Latest 8-K
Oct 15, 2026
Regulation FD disclosure
Last earnings release
Aug 3, 2026
$1.79 vs $1.70 · ▼ 8.4%
Filings on file
509
since 2017, 241 insider forms
What happened, last 12 months#
Every earnings release with its print, every report with its quarter, the other 8-Ks by the headline of the press release they furnish or by their items, the proxy statements, and each day an insider bought or sold — newest first, each line opening the filing on EDGAR. The index by form and year follows.
October 2026
- Oct 158-K8-K · Regulation FD disclosure
September 2026
August 2026
July 2026
- Jul 218-K8-K · Other events
June 2026
- Jun 25Insider saleThomas John Charles (EVP, General Counsel) sold 1,000 shares for $347K at $347.27 under a 10b5-1 plan
- Jun 4Insider saleKrishnan Krish S (President and CEO · Director · 10% owner) sold 25,000 shares for $7.7M at $300.75–$312.23 under a 10b5-1 plan
- Jun 4Insider saleKrishnan Suma (President, R&D · Director · 10% owner) sold 25,000 shares for $7.7M at $300.75–$311.65 under a 10b5-1 plan
May 2026
- May 26Insider saleThomas John Charles (EVP, General Counsel) sold 642 shares for $194K at $302.03 under a 10b5-1 plan
- May 208-K8-K · Shareholder vote results
- May 4ReportQuarterly report, Q1 2026 — revenue $116.4M (+32% y/y), net income $55.9M, EPS $1.83
- May 48-K8-K · Krystal Biotech Announces First Quarter 2026 Financial and Operating ResultsFinancial statements and exhibits
April 2026
- Apr 3ProxyProxy · Annual report to shareholders
- Apr 3ProxyProxy · Additional proxy materials
- Apr 3ProxyProxy · Proxy statement
March 2026
- Mar 4Insider saleKrishnan Suma (President, R&D · Director · 10% owner) sold 25,000 shares for $6.6M at $257.32–$266.42 under a 10b5-1 plan
- Mar 4Insider saleKrishnan Krish S (President and CEO · Director · 10% owner) sold 25,000 shares for $6.6M at $257.31–$266.56 under a 10b5-1 plan
- Mar 2Insider saleROMANO KATHRYN (Chief Accounting Officer) sold 750 shares for $201K at $267.60 under a 10b5-1 plan
February 2026
- Feb 27Insider saleJANNEY DANIEL (Director) sold 11,803 shares for $3.3M at $275.45–$276.17 under a 10b5-1 plan
- Feb 26Insider saleJANNEY DANIEL (Director) sold 7,741 shares for $2.1M at $275.28–$276.32 under a 10b5-1 plan
- Feb 25Insider saleJANNEY DANIEL (Director) sold 700 shares for $193K at $275.00 under a 10b5-1 plan
- Feb 24Insider saleJANNEY DANIEL (Director) sold 51,720 shares for $13.8M at $262.91–$274.90 under a 10b5-1 plan
- Feb 19Insider saleROSSI DINO A (Director) sold 18,950 shares for $5.0M at $260.49–$262.10
- Feb 17EarningsEarnings release — EPS $1.70 vs $1.62 est. (+4.9%); revenue $107.1M (+18% y/y) 4.1%
- Feb 17ReportAnnual report, FY2025 — revenue $389.1M (+34% y/y), net income $204.8M, EPS $6.84
- Feb 9Insider saleROMANO KATHRYN (Chief Accounting Officer) sold 12,500 shares for $3.4M at $270.56–$277.88 under a 10b5-1 plan
January 2026
- Jan 128-K8-K · Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare ConferenceResults of operations; Regulation FD disclosure
- Jan 88-K8-K · Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic FibrosisRegulation FD disclosure
December 2025
- Dec 238-K8-K · Directors or officers; compensation
November 2025
October 2025
- Oct 228-K8-K · Other events
Insider transactions#
What officers, directors and 10% holders reported on Forms 4 and 5 over the last 13 months, from the documents themselves: one insider’s trades of one kind on one day are one row, with the shares, the price range and the total as filed. Open-market buys and sells first; awards, exercises, tax withholding, gifts and employee-plan purchases are grouped below them.
Over the last 13 months insiders sold $83.3M in 16 sales and bought nothing on the open market; 41 other transactions (awards, exercises, tax withholding, gifts and plan purchases).
| Date | Insider |
|---|---|
| Sep 4, 2026Form 4 | Krishnan Krish SPresident and CEO · Director · 10% ownerSold · $9.0M · 25,000 sh · 10b5-1 |
| Sep 4, 2026Form 4 | Krishnan SumaPresident, R&D · Director · 10% ownerSold · $9.0M · 25,000 sh · 10b5-1 |
| Aug 14, 2026Form 4 | ROSSI DINO ADirectorSold · $8.2M · 25,000 sh |
| Jun 25, 2026Form 4 | Thomas John CharlesEVP, General CounselSold · $347K · 1,000 sh · 10b5-1 |
| Jun 4, 2026Form 4 | Krishnan Krish SPresident and CEO · Director · 10% ownerSold · $7.7M · 25,000 sh · 10b5-1 |
| Jun 4, 2026Form 4 | Krishnan SumaPresident, R&D · Director · 10% ownerSold · $7.7M · 25,000 sh · 10b5-1 |
| May 26, 2026Form 4 | Thomas John CharlesEVP, General CounselSold · $194K · 642 sh · 10b5-1 |
| Mar 4, 2026Form 4 | Krishnan SumaPresident, R&D · Director · 10% ownerSold · $6.6M · 25,000 sh · 10b5-1 |
| Mar 4, 2026Form 4 | Krishnan Krish SPresident and CEO · Director · 10% ownerSold · $6.6M · 25,000 sh · 10b5-1 |
| Mar 2, 2026Form 4 | ROMANO KATHRYNChief Accounting OfficerSold · $201K · 750 sh · 10b5-1 |
| Feb 27, 2026Form 4 | JANNEY DANIELDirectorSold · $3.3M · 11,803 sh · 10b5-1 |
| Feb 26, 2026Form 4 | JANNEY DANIELDirectorSold · $2.1M · 7,741 sh · 10b5-1 |
| Feb 25, 2026Form 4 | JANNEY DANIELDirectorSold · $193K · 700 sh · 10b5-1 |
| Feb 24, 2026Form 4 | JANNEY DANIELDirectorSold · $13.8M · 51,720 sh · 10b5-1 |
| Feb 19, 2026Form 4 | ROSSI DINO ADirectorSold · $5.0M · 18,950 sh |
| Feb 9, 2026Form 4 | ROMANO KATHRYNChief Accounting OfficerSold · $3.4M · 12,500 sh · 10b5-1 |
Awards, exercises, withholding and plan purchases · 41 transactions
| Date | Insider |
|---|---|
| Sep 14, 2026Form 4 | ROSSI DINO ADirectorAward · Stock Option (Right to Buy) · $0 · 1,187 sh |
| Sep 14, 2026Form 4 | Gangolli Julian SDirectorAward · Stock Option (Right to Buy) · $0 · 1,187 sh |
| Sep 14, 2026Form 4 | JANNEY DANIELDirectorAward · Stock Option (Right to Buy) · $0 · 1,187 sh |
| Sep 14, 2026Form 4 | Mason ChristopherDirectorAward · Stock Option (Right to Buy) · $0 · 1,187 sh |
| Sep 14, 2026Form 4 | Sutherland Everett RandDirectorAward · Stock Option (Right to Buy) · $0 · 1,187 sh |
| Sep 14, 2026Form 4 | Mazzacco CatherineDirectorAward · Stock Option (Right to Buy) · $0 · 1,187 sh |
| Sep 14, 2026Form 4 | ROSSI DINO ADirectorAward · Restricted Stock Units · $0 · 471 sh |
| Sep 14, 2026Form 4 | Gangolli Julian SDirectorAward · Restricted Stock Units · $0 · 471 sh |
| Sep 14, 2026Form 4 | JANNEY DANIELDirectorAward · Restricted Stock Award · $0 · 471 sh |
| Sep 14, 2026Form 4 | Mason ChristopherDirectorAward · Restricted Stock Units · $0 · 471 sh |
| Sep 14, 2026Form 4 | Sutherland Everett RandDirectorAward · Restricted Stock Units · $0 · 471 sh |
| Sep 14, 2026Form 4 | Mazzacco CatherineDirectorAward · Restricted Stock Units · $0 · 471 sh |
| Aug 14, 2026Form 4 | ROSSI DINO ADirectorGift · $0 · 3,691 sh |
| Jun 25, 2026Form 4 | Thomas John CharlesEVP, General CounselExercise or conversion · $179K · 1,000 sh · 10b5-1 |
| Jun 25, 2026Form 4 | Thomas John CharlesEVP, General CounselExercise or conversion · Stock Option (Right to Buy) · $0 · 1,000 sh · 10b5-1 |
| Feb 27, 2026Form 4 | Krishnan Krish SPresident and CEO · Director · 10% ownerTax withholding · $8.4M · 30,584 sh |
| Feb 27, 2026Form 4 | Krishnan SumaPresident, R&D · Director · 10% ownerTax withholding · $8.4M · 30,584 sh |
| Feb 27, 2026Form 4 | ROMANO KATHRYNChief Accounting OfficerTax withholding · $965K · 3,502 sh · 10b5-1 |
| Feb 27, 2026Form 4 | Krishnan Krish SPresident and CEO · Director · 10% ownerExercise or conversion · $0 · 67,225 sh |
| Feb 27, 2026Form 4 | Krishnan SumaPresident, R&D · Director · 10% ownerExercise or conversion · $0 · 67,225 sh |
| Feb 27, 2026Form 4 | Krishnan Krish SPresident and CEO · Director · 10% ownerAward · Stock Option (Right to Buy) · $0 · 45,249 sh |
| Feb 27, 2026Form 4 | Krishnan SumaPresident, R&D · Director · 10% ownerAward · Performance Stock Units · $0 · 43,536 sh |
| Feb 27, 2026Form 4 | Krishnan Krish SPresident and CEO · Director · 10% ownerExercise or conversion · Performance Stock Units · $0 · 26,250 sh |
| Feb 27, 2026Form 4 | Krishnan SumaPresident, R&D · Director · 10% ownerExercise or conversion · Performance Stock Units · $0 · 22,500 sh |
| Feb 27, 2026Form 4 | Krishnan Krish SPresident and CEO · Director · 10% ownerAward · Restricted Stock Units · $0 · 18,140 sh |
| Feb 27, 2026Form 4 | Krishnan SumaPresident, R&D · Director · 10% ownerAward · Stock Option (Right to Buy) · $0 · 18,100 sh |
| Feb 27, 2026Form 4 | Krishnan Krish SPresident and CEO · Director · 10% ownerExercise or conversion · Restricted Stock Units · $0 · 14,475 sh |
| Feb 27, 2026Form 4 | ROMANO KATHRYNChief Accounting OfficerAward · Stock Option (Right to Buy) · $0 · 13,575 sh · 10b5-1 |
| Feb 27, 2026Form 4 | ROMANO KATHRYNChief Accounting OfficerExercise or conversion · $0 · 8,050 sh · 10b5-1 |
| Feb 27, 2026Form 4 | ROMANO KATHRYNChief Accounting OfficerExercise or conversion · Performance Stock Units · $0 · 7,500 sh · 10b5-1 |
| Feb 27, 2026Form 4 | Krishnan SumaPresident, R&D · Director · 10% ownerAward · Restricted Stock Units · $0 · 7,256 sh |
| Feb 27, 2026Form 4 | ROMANO KATHRYNChief Accounting OfficerAward · Restricted Stock Units · $0 · 5,442 sh · 10b5-1 |
| Feb 27, 2026Form 4 | Krishnan SumaPresident, R&D · Director · 10% ownerExercise or conversion · Restricted Stock Units · $0 · 4,000 sh |
| Feb 27, 2026Form 4 | ROMANO KATHRYNChief Accounting OfficerExercise or conversion · Restricted Stock Units · $0 · 550 sh · 10b5-1 |
| Feb 24, 2026Form 4 | JANNEY DANIELDirectorExercise or conversion · $93K · 37,895 sh · 10b5-1 |
| Feb 24, 2026Form 4 | JANNEY DANIELDirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 37,895 sh · 10b5-1 |
| Feb 19, 2026Form 4 | ROSSI DINO ADirectorExercise or conversion · $167K · 18,950 sh |
| Feb 19, 2026Form 4 | ROSSI DINO ADirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 18,950 sh |
| Feb 9, 2026Form 4 | ROMANO KATHRYNChief Accounting OfficerExercise or conversion · $794K · 12,500 sh · 10b5-1 |
| Feb 9, 2026Form 4 | ROMANO KATHRYNChief Accounting OfficerExercise or conversion · Stock Option (Right to Buy) · $0 · 12,500 sh · 10b5-1 |
| Feb 9, 2026Form 4 | ROMANO KATHRYNChief Accounting OfficerGift · $0 · 750 sh · 10b5-1 |
Reports and proxy statements#
Annual reports (10-K, 20-F, 40-F), quarterly reports (10-Q), current reports (8-K, 6-K) and proxy statements, newest first. An 8-K that furnishes a press release is headed by the release’s headline, its items beneath; any other 8-K is described by its items. A form opens the press release where there is one, else the document on EDGAR, or the filing’s index where it furnishes other exhibits.
2026 · 14 filings
| Filed | What it is |
|---|---|
| Oct 15, 20268-K | Regulation FD disclosure |
| Aug 3, 20268-K | Earnings release — EPS $1.79 vs $1.70 est. (+5.3%); revenue $119.2M (+24% y/y) 8.4% |
| Aug 3, 202610-Q | Quarterly report, Q2 2026 — revenue $119.2M (+24% y/y), net income $54.8M, EPS $1.79 |
| Jul 21, 20268-K | Other events |
| May 20, 20268-K | Shareholder vote results |
| May 4, 20268-K | Krystal Biotech Announces First Quarter 2026 Financial and Operating ResultsFinancial statements and exhibits |
| May 4, 202610-Q | Quarterly report, Q1 2026 — revenue $116.4M (+32% y/y), net income $55.9M, EPS $1.83 |
| Apr 3, 2026ARS | Annual report to shareholders |
| Apr 3, 2026DEFA14A | Additional proxy materials |
| Apr 3, 2026DEF 14A | Proxy statement |
| Feb 17, 20268-K | Earnings release — EPS $1.70 vs $1.62 est. (+4.9%); revenue $107.1M (+18% y/y) 4.1% |
| Feb 17, 202610-K | Annual report, FY2025 — revenue $389.1M (+34% y/y), net income $204.8M, EPS $6.84 |
| Jan 12, 20268-K | Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare ConferenceResults of operations; Regulation FD disclosure |
| Jan 8, 20268-K | Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic FibrosisRegulation FD disclosure |
2025 · 22 filings
| Filed | What it is |
|---|---|
| Dec 23, 20258-K | Directors or officers; compensation |
| Nov 3, 20258-K | Earnings release — EPS $2.66 vs $1.12 est. (+137.5%); revenue $97.8M (+17% y/y) 0.2% |
| Nov 3, 202510-Q | Quarterly report, Q3 2025 — revenue $97.8M (+17% y/y), net income $79.4M, EPS $2.66 |
| Oct 22, 20258-K | Other events |
| Aug 4, 20258-K | Results of operations |
| Aug 4, 202510-Q | Quarterly report, Q2 2025 — revenue $96.0M (+37% y/y), net income $38.3M, EPS $1.29 |
| Jul 25, 20258-K | Regulation FD disclosure |
| Jul 24, 20258-K | Regulation FD disclosure |
| Jul 9, 20258-K | Regulation FD disclosure |
| Jun 2, 20258-K | Other events |
| May 19, 20258-K | Shareholder vote results |
| May 13, 20258-K | Regulation FD disclosure |
| May 6, 20258-K | Results of operations |
| May 6, 202510-Q | Quarterly report, Q1 2025 — revenue $88.2M (+95% y/y), net income $35.7M, EPS $1.20 |
| May 6, 20258-K | Regulation FD disclosure |
| Apr 28, 20258-K | Regulation FD disclosure |
| Apr 3, 2025ARS | Annual report to shareholders |
| Apr 3, 2025DEFA14A | Additional proxy materials |
| Apr 3, 2025DEF 14A | Proxy statement |
| Feb 28, 20258-K | Financial statements and exhibits |
| Feb 19, 20258-K | Regulation FD disclosure |
| Feb 19, 202510-K | Annual report, FY2024 — revenue $290.5M (+473% y/y), net income $89.2M, EPS $3.00 |
2024 · 15 filings
| Filed | What it is |
|---|---|
| Dec 18, 20248-K | Regulation FD disclosure |
| Dec 12, 20248-K | Regulation FD disclosure |
| Nov 4, 202410-Q | Quarterly report, Q3 2024 — revenue $83.8M (+880% y/y), net income $27.2M, EPS $0.91 |
| Nov 4, 20248-K | Results of operations |
| Aug 28, 20248-K | Regulation FD disclosure |
| Aug 5, 202410-Q | Quarterly report, Q2 2024 — revenue $70.3M, net income $15.6M, EPS $0.53 |
| Aug 5, 20248-K | Results of operations |
| May 21, 20248-K | Shareholder vote results |
| May 8, 20248-K | Regulation FD disclosure |
| May 6, 202410-Q | Quarterly report, Q1 2024 — revenue $45.3M, net income $932K, EPS $0.03 |
| May 6, 20248-K | Results of operations |
| Apr 4, 2024DEFA14A | Additional proxy materials |
| Apr 4, 2024DEF 14A | Proxy statement |
| Feb 26, 20248-K | Results of operations |
| Feb 26, 202410-K | Annual report, FY2023 — revenue $50.7M, net income $10.9M, EPS $0.39 |
2023 · 20 filings — 14 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Nov 6, 202310-Q | Quarterly report, Q3 2023 — revenue $8.6M, net income $80.7M |
| Aug 7, 202310-Q | Quarterly report |
| May 8, 202310-Q | Quarterly report, Q1 2023 — revenue $0, net income −$45.3M, EPS −$1.76 |
| Apr 4, 2023DEFA14A | Additional proxy materials |
| Apr 4, 2023DEF 14A | Proxy statement |
| Feb 27, 202310-K | Annual report, FY2022 — revenue $0, net income −$140.0M, EPS −$5.49 |
14 current reports (8-K) not listed; the year is on EDGAR.
2022 · 21 filings — 15 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Nov 7, 202210-Q | Quarterly report, Q3 2022 — revenue $0, net income −$29.9M, EPS −$1.17 |
| Aug 8, 202210-Q | Quarterly report, Q2 2022 — net income −$28.1M, EPS −$1.10 |
| May 9, 202210-Q | Quarterly report, Q1 2022 — net income −$50.0M, EPS −$1.99 |
| Apr 7, 2022DEFA14A | Additional proxy materials |
| Apr 7, 2022DEF 14A | Proxy statement |
| Feb 28, 202210-K | Annual report, FY2021 — revenue $0, net income −$69.6M, EPS −$3.13 |
15 current reports (8-K) not listed; the year is on EDGAR.
2021 · 23 filings — 16 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
| Filed | What it is |
|---|---|
| Nov 8, 202110-Q | Quarterly report, Q3 2021 — net income −$15.6M, EPS −$0.70 |
| Aug 9, 202110-Q | Quarterly report, Q2 2021 — net income −$16.4M, EPS −$0.74 |
| May 10, 202110-Q | Quarterly report, Q1 2021 — net income −$15.8M, EPS −$0.74 |
| Apr 6, 2021DEFA14A | Additional proxy materials |
| Apr 6, 2021DEF 14A | Proxy statement |
| Mar 1, 202110-K | Annual report, FY2020 — net income −$32.2M, EPS −$1.71 |
17 current reports (8-K) not listed; the year is on EDGAR.
2020 · 18 filings — 12 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Nov 9, 202010-Q | Quarterly report, Q3 2020 — net income −$9.6M, EPS −$0.49 |
| Aug 7, 202010-Q | Quarterly report, Q2 2020 — net income −$6.8M, EPS −$0.37 |
| May 8, 2020DEFA14A | Additional proxy materials |
| May 4, 202010-Q | Quarterly report, Q1 2020 — net income −$5.3M |
| Apr 13, 2020DEF 14A | Proxy statement |
| Mar 10, 202010-K | Annual report, FY2019 — net income −$19.1M |
12 current reports (8-K) not listed; the year is on EDGAR.
2019 · 17 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
| Filed | What it is |
|---|---|
| Nov 4, 201910-Q | Quarterly report, Q3 2019 — net income −$4.3M |
| Aug 5, 201910-Q | Quarterly report, Q2 2019 — net income −$5.3M |
| May 7, 201910-Q | Quarterly report, Q1 2019 — net income −$4.1M |
| Apr 15, 2019DEFA14A | Additional proxy materials |
| Apr 15, 2019DEF 14A | Proxy statement |
| Mar 12, 201910-K | Annual report |
11 current reports (8-K) not listed; the year is on EDGAR.
2018 · 13 filings — 8 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
| Filed | What it is |
|---|---|
| Nov 5, 201810-Q | Quarterly report, Q3 2018 — net income −$2.8M |
| Aug 6, 201810-Q | Quarterly report, Q2 2018 — net income −$2.3M |
| May 7, 201810-Q | Quarterly report, Q1 2018 — net income −$2.1M |
| Apr 20, 2018DEF 14A | Proxy statement |
| Mar 12, 201810-K | Annual report, FY2017 — net income −$7.9M |
8 current reports (8-K) not listed; the year is on EDGAR.
Insider, ownership and other filings#
Insider ownership (Forms 3, 4, 5 and 144), beneficial ownership (Schedules 13D and 13G), registration and prospectus (S-1, S-3, S-8, 424B and related) and the rest, counted by year, with the newest 25 of each of the latest 3 years shown. A Form 4 is one insider’s transaction report; a 13G is a passive holder above five percent.
2026 · 44 filings — 22 × 4, 17 × 144, 2 × 3 and 2 other forms
| Filed | What it is |
|---|---|
| Sep 16, 20264 | Insider transaction (Form 4) |
| Sep 16, 20264 | Insider transaction (Form 4) |
| Sep 16, 20264 | Insider transaction (Form 4) |
| Sep 16, 20264 | Insider transaction (Form 4) |
| Sep 16, 20264 | Insider transaction (Form 4) |
| Sep 16, 20264 | Insider transaction (Form 4) |
| Sep 4, 20264 | Insider transaction (Form 4) |
| Sep 4, 20264 | Insider transaction (Form 4) |
| Sep 4, 2026144 | Notice of proposed sale (Form 144) |
| Sep 4, 2026144 | Notice of proposed sale (Form 144) |
| Aug 14, 20264 | Insider transaction (Form 4) |
| Aug 14, 2026144 | Notice of proposed sale (Form 144) |
| Jun 26, 20264 | Insider transaction (Form 4) |
| Jun 25, 2026144 | Notice of proposed sale (Form 144) |
| Jun 5, 20264 | Insider transaction (Form 4) |
| Jun 5, 20264 | Insider transaction (Form 4) |
| Jun 4, 2026144 | Notice of proposed sale (Form 144) |
| Jun 4, 2026144 | Notice of proposed sale (Form 144) |
| May 27, 20264 | Insider transaction (Form 4) |
| May 26, 2026144 | Notice of proposed sale (Form 144) |
| May 4, 2026SCHEDULE 13G/A | Other filings |
| Apr 29, 2026SCHEDULE 13G | Other filings |
| Mar 27, 2026SCHEDULE 13G/A | Other filings |
| Mar 6, 20263 | Initial insider holdings (Form 3) |
| Mar 6, 20263 | Initial insider holdings (Form 3) |
The newest 25 of 44 shown; the full year is on EDGAR.
2025 · 25 filings — 17 × 4, 7 × 144, 1 × SCHEDULE 13G
| Filed | What it is |
|---|---|
| Dec 5, 20254 | Insider transaction (Form 4) |
| Dec 5, 20254 | Insider transaction (Form 4) |
| Dec 4, 2025144 | Notice of proposed sale (Form 144) |
| Dec 4, 2025144 | Notice of proposed sale (Form 144) |
| Jul 16, 20254 | Insider transaction (Form 4) |
| Jul 16, 20254 | Insider transaction (Form 4) |
| Jul 11, 20254 | Insider transaction (Form 4) |
| Jul 11, 20254 | Insider transaction (Form 4) |
| Jul 9, 2025144 | Notice of proposed sale (Form 144) |
| Jul 9, 2025144 | Notice of proposed sale (Form 144) |
| Jun 30, 20254 | Insider transaction (Form 4) |
| Jun 30, 20254 | Insider transaction (Form 4) |
| Jun 30, 20254 | Insider transaction (Form 4) |
| Jun 30, 20254 | Insider transaction (Form 4) |
| Jun 30, 20254 | Insider transaction (Form 4) |
| Jun 30, 20254 | Insider transaction (Form 4) |
| Mar 13, 20254 | Insider transaction (Form 4) |
| Mar 13, 20254 | Insider transaction (Form 4) |
| Mar 13, 2025144 | Notice of proposed sale (Form 144) |
| Mar 13, 2025144 | Notice of proposed sale (Form 144) |
| Feb 28, 20254 | Insider transaction (Form 4) |
| Feb 28, 20254 | Insider transaction (Form 4) |
| Feb 28, 20254 | Insider transaction (Form 4) |
| Feb 27, 2025144 | Notice of proposed sale (Form 144) |
| Feb 5, 2025SCHEDULE 13G | Other filings |
2024 · 48 filings — 24 × 4, 12 × 144, 9 × SC 13G/A and 2 other forms
| Filed | What it is |
|---|---|
| Dec 13, 20244 | Insider transaction (Form 4) |
| Dec 13, 20244 | Insider transaction (Form 4) |
| Dec 13, 2024144 | Notice of proposed sale (Form 144) |
| Dec 13, 2024144 | Notice of proposed sale (Form 144) |
| Nov 14, 2024SC 13G/A | Passive holder above 5% (Schedule 13G), amended |
| Nov 12, 2024SC 13G/A | Passive holder above 5% (Schedule 13G), amended |
| Oct 16, 2024SC 13G | Passive holder above 5% (Schedule 13G) |
| Sep 13, 20244 | Insider transaction (Form 4) |
| Sep 13, 20244 | Insider transaction (Form 4) |
| Sep 13, 20244 | Insider transaction (Form 4) |
| Sep 12, 2024144 | Notice of proposed sale (Form 144) |
| Sep 12, 2024144 | Notice of proposed sale (Form 144) |
| Jul 10, 2024SC 13G/A | Passive holder above 5% (Schedule 13G), amended |
| Jul 8, 2024SC 13G/A | Passive holder above 5% (Schedule 13G), amended |
| Jul 1, 20244 | Insider transaction (Form 4) |
| Jul 1, 20244 | Insider transaction (Form 4) |
| Jul 1, 20244 | Insider transaction (Form 4) |
| Jul 1, 20244 | Insider transaction (Form 4) |
| Jul 1, 20244 | Insider transaction (Form 4) |
| Jul 1, 20244 | Insider transaction (Form 4) |
| Jun 11, 20244 | Insider transaction (Form 4) |
| Jun 11, 20244 | Insider transaction (Form 4) |
| Jun 11, 2024144 | Notice of proposed sale (Form 144) |
| Jun 11, 2024144 | Notice of proposed sale (Form 144) |
| May 22, 20244 | Insider transaction (Form 4) |
The newest 25 of 48 shown; the full year is on EDGAR.
2023 · 66 filings — 32 × 4, 20 × 144, 5 × SC 13G/A and 7 other forms
Counted, not listed; the year is on EDGAR.
2022 · 26 filings — 19 × 4, 4 × SC 13G/A, 1 × 3 and 2 other forms
Counted, not listed; the year is on EDGAR.
2021 · 31 filings — 14 × 4, 7 × SC 13G/A, 3 × 3 and 4 other forms
Counted, not listed; the year is on EDGAR.
2020 · 25 filings — 10 × 4, 5 × SC 13G/A, 4 × SC 13G and 4 other forms
Counted, not listed; the year is on EDGAR.
2019 · 17 filings — 7 × 4, 5 × SC 13G/A, 3 × 424B5 and 2 other forms
Counted, not listed; the year is on EDGAR.
2018 · 23 filings — 11 × 4, 5 × SC 13G, 2 × 424B5 and 5 other forms
Counted, not listed; the year is on EDGAR.
2017 · 37 filings — 7 × 3, 6 × 3/A, 5 × CORRESP and 14 other forms
Counted, not listed; the year is on EDGAR.
About this data#
Krystal Biotech Inc. (KRYS) has 509 filings on EDGAR going back to 2017: 9 annual reports, 27 quarterly reports and 112 current reports, plus proxy statements, insider forms and ownership schedules. Its latest annual report, a 10-K, was filed on Feb 17, 2026 for the fiscal year ended Dec 31, 2025. The most recent 8-K, on Oct 15, 2026, covered regulation fd disclosure. Over the last 13 months insiders sold $83.3M in 16 sales and bought nothing on the open market; 41 other transactions (awards, exercises, tax withholding, gifts and plan purchases). Not investment advice.
Every row is a filing EDGAR lists for the registrants that have been Krystal Biotech Inc., read from the SEC’s submissions index each morning; a filing accepted after that read appears the next day. Where a company changed its filing entity (a holding-company reorganisation, Google into Alphabet) the predecessor’s filings are shown for the years it filed as the company, derived from the filings themselves. Dates are the filing date; the period is the report’s own. The latest 3 years of reports are listed in full, the next years to 10 without their 8-Ks, and older years are counted; the other forms are counted too, with the newest 25 of each of the latest 3 years shown. Insider transactions are the Form 4 and Form 5 documents themselves, filed since January 2026, every number as the insider filed it: a day’s lots are summed, a blank price adds its shares and no dollars, and a purchase through an employee stock plan is a plan purchase, not insider buying. An 8-K’s headline is the first line of the press release it furnishes (Exhibit 99), read from the filing and shown word for word; where two independent readings of the exhibit do not agree, the 8-K is described by its items instead. The documents stay on sec.gov, public domain, and every link opens the SEC’s copy. ChartRow does not summarise or interpret filings.
FAQ#
- Where can I read KRYS's latest 10-K?
- KRYS's latest annual report, a 10-K, was filed on Feb 17, 2026 for the fiscal year ended Dec 31, 2025. It is linked above and opens on EDGAR, the SEC's own site, where every exhibit is also listed.
- When did KRYS last file an 8-K?
- On Oct 15, 2026 it covered regulation fd disclosure. An 8-K reports a material event between quarterly reports; the one that furnishes the quarter's results is filed under Item 2.02, last on Aug 3, 2026.
- Are KRYS insiders buying or selling?
- Over the last 13 months insiders sold $83.3M in 16 sales and bought nothing on the open market; 41 other transactions (awards, exercises, tax withholding, gifts and plan purchases). The most recent sale: Krishnan Krish S (President and CEO · Director · 10% owner) sold 25,000 shares on Sep 4, 2026 for $9.0M, under a 10b5-1 plan. Every figure is as the insider filed it on Form 4; a sale under a 10b5-1 plan was scheduled in advance.
- How many SEC filings has KRYS made?
- 509 filings are on EDGAR under the registrant records that have been Krystal Biotech Inc., going back to 2017; 241 of them are insider ownership forms (Forms 3, 4, 5 and 144).